{"id":9605,"date":"2020-06-16T17:21:30","date_gmt":"2020-06-16T11:51:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9605"},"modified":"2022-10-13T10:53:55","modified_gmt":"2022-10-13T05:23:55","slug":"latest-covid-happenings-and-pharma-sector","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector","title":{"rendered":"HCQ\/ CQ failure; AZ\/ Catalent\u2019s deal; Sinovac\u2019s CoronaVac and Lilly\u2019s Olumiant trial results"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f607e436e25\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f607e436e25\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector\/#The_US_FDA_nullified_the_Emergency_Use_Authorization_EUA_granted_to_chloroquine_phosphate_and_hydroxychloroquine_sulfate_to_treat_COVID-19\" >The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector\/#Eli_Lilly_has_announced_the_launch_of_Phase_II_trial_of_its_rheumatoid_arthritis_drug_Olumiant_baricitinib_for_the_patients_suffering_from_COVID-19\" >Eli Lilly has announced the launch of Phase II trial of its rheumatoid arthritis drug Olumiant (baricitinib) for the patients suffering from COVID-19.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector\/#Catalent_Biologics_has_made_public_the_details_of_the_deal_with_AstraZeneca_to_develop_AZD1222_an_experimental_vaccine_to_prevent_coronavirus_infection_COVID-19\" >Catalent Biologics has made public the details of the deal with AstraZeneca to develop AZD1222, an experimental vaccine to prevent coronavirus infection COVID-19.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector\/#Sinovac_Biotech_announced_promising_results_from_Phase_III_clinical_trials_of_its_COVID-19_vaccine_CoronaVac\" >Sinovac Biotech announced promising results from Phase I\/II clinical trials of its COVID-19 vaccine, CoronaVac.<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_US_FDA_nullified_the_Emergency_Use_Authorization_EUA_granted_to_chloroquine_phosphate_and_hydroxychloroquine_sulfate_to_treat_COVID-19\"><\/span><strong>The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The regulatory authority had granted the EUA to malarial drugs to be used in hospitalized <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">COVID-19<\/a> patients only when a clinical trial was unavailable, or participation in a clinical trial was not feasible.<\/p>\n\n\n\n<p>The agency announced that the drugs have failed to meet the criteria required to be put under EUA. Moreover, ongoing research has revealed that the boxed warnings and side effects such as cardiac arrest and stroke that came along with the use of drugs outweigh the benefits the drugs have to offer.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/hydroxychloroquine-and-covid-19\/\">Hydroxychloroquine<\/a> has long been available in the market as an approved drug for the treatment of malaria, and autoimmune diseases such as lupus.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Eli_Lilly_has_announced_the_launch_of_Phase_II_trial_of_its_rheumatoid_arthritis_drug_Olumiant_baricitinib_for_the_patients_suffering_from_COVID-19\"><\/span><strong>Eli Lilly has announced the launch of Phase II trial of its rheumatoid arthritis drug Olumiant (baricitinib) for the patients suffering from COVID-19.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The company is teamed up with the National Institute of Allergy and Infectious Diseases (NIAID) and intends to enrol approximately 400 patients in the double-blind, placebo-controlled study. The patients would be selected on the basis of the presence of at least one of the elevated markers of inflammation and do not require invasive mechanical ventilation.<\/p>\n\n\n\n<p>Sold under the brand name Olumiant, <a href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly\/\">baricitinib is an approved drug<\/a> \u2013 a Janus kinase (JAK) inhibitor \u2013 for rheumatoid arthritis (RA) patients whose disease was not controlled by tumor necrosis factor (TNF) antagonists used to treat the disease. The drug is already in the trials sponsored by NIAID in combination with Gilead\u2019s remdesivir for the treatment of Covid-19 in the USA.<\/p>\n\n\n\n<p>However, Lilly is not the only of first player testing its RA drug to treat COVID-19 patients. Roche\u2019s Actemra and Regeneron\/ Sanofi\u2019s <a href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-janssen-silver-therapeutics-sanofi-regeneron\/\">Kevzara<\/a> are also in the battlefield fighting COVID-19.<\/p>\n\n\n\n<p>Moreover, the company is also <a href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly\/\">partnered with Junshi Biosciences<\/a> to co-develop JS016, a recombinant fully human monoclonal neutralizing antibody. This is the second monoclonal neutralizing antibody under <a href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abcellera-eli-lilly-abbvie-gilead\/\">development by Lilly after LY-CoV555<\/a>, which is thought to be the first potential medicine that can treat as well as prevent COVID-19 infection.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Catalent_Biologics_has_made_public_the_details_of_the_deal_with_AstraZeneca_to_develop_AZD1222_an_experimental_vaccine_to_prevent_coronavirus_infection_COVID-19\"><\/span><strong>Catalent Biologics has made public the details of the deal with AstraZeneca to develop AZD1222, an experimental vaccine to prevent coronavirus infection COVID-19.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Catalent Biologics, a global provider of advanced delivery technologies, development, and manufacturing solutions to Life Science vertical has announced to ramp up the production of the AZ and Oxford\u2019s adenovirus vector-based <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a> vaccine AZD1222.<\/p>\n\n\n\n<p>Catalent will provide vial filling and packaging capacity to AstraZeneca, supporting the dedicated production of AZD1222. The company will help Oxford in mass production of the vaccine by preparing for the manufacturing facility and managing the supplies of hundreds of doses of vaccines after it gets approved.<\/p>\n\n\n\n<p>Earlier, AstraZeneca also tied up with Europe\u2019s Inclusive Vaccines Alliance (IVA) to supply up to 400 million doses of its vaccine across the globe and a USD 87 Million deal Emergent BioSolutions to manufacture the vaccine for the US market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sinovac_Biotech_announced_promising_results_from_Phase_III_clinical_trials_of_its_COVID-19_vaccine_CoronaVac\"><\/span><strong>Sinovac Biotech announced promising results from Phase I\/II clinical trials of its COVID-19 vaccine, CoronaVac.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Beijing-based Sinovac Biotech\u2019s COVID-19 vaccine, CoronaVac has emerged as a promising candidate after the company released the results of its trials showcasing it as favourable in both immunogenicity and safety.<\/p>\n\n\n\n<p>The trial had enrolled a total of 743 healthy volunteers in Phase I\/II trial of age from 18 to 59 years. There were no serious side effects reported, and the vaccine was demonstrated to be neutralizing antibodies 14 days after dosing. The antibody seroconversion rate is higher than 90%, which suggests the vaccine can induce a positive immune response.<\/p>\n\n\n\n<p>Moreover, the company plans to submit the report on its trial results to China\u2019s National Medical Products Administration (NMPA) and plans to begin the Phase III trial in collaboration with the Instituto Butantan in Brazil.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19. The regulatory authority had granted the EUA to malarial drugs to be used in hospitalized COVID-19 patients only when a clinical trial was unavailable, or participation in a clinical trial was not feasible. The agency announced [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9645,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,18471,7859,10830,228,18469,704,18470,2019,18472],"industry":[17225],"therapeutic_areas":[17227,17231,17243],"class_list":["post-9605","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-catalent-biologics","tag-coronavirus","tag-covid-19","tag-eli-lilly","tag-emergency-use-authorization","tag-fda","tag-olumiant","tag-rheumatoid-arthritis","tag-sinovac-biotech","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>HCQ\/ CQ fails; AZ\/ Catalent\u2019s deal; Sinovac\u2019s CoronaVac, Lilly\u2019s Olumiant<\/title>\n<meta name=\"description\" content=\"The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HCQ\/ CQ fails; AZ\/ Catalent\u2019s deal; Sinovac\u2019s CoronaVac, Lilly\u2019s Olumiant\" \/>\n<meta property=\"og:description\" content=\"The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-16T11:51:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-13T05:23:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/16171252\/Latest-Phrma-Happenings.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HCQ\/ CQ fails; AZ\/ Catalent\u2019s deal; Sinovac\u2019s CoronaVac, Lilly\u2019s Olumiant","description":"The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector","og_locale":"en_US","og_type":"article","og_title":"HCQ\/ CQ fails; AZ\/ Catalent\u2019s deal; Sinovac\u2019s CoronaVac, Lilly\u2019s Olumiant","og_description":"The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19.","og_url":"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-06-16T11:51:30+00:00","article_modified_time":"2022-10-13T05:23:55+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/16171252\/Latest-Phrma-Happenings.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector","url":"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector","name":"HCQ\/ CQ fails; AZ\/ Catalent\u2019s deal; Sinovac\u2019s CoronaVac, Lilly\u2019s Olumiant","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/16171252\/Latest-Phrma-Happenings.jpg","datePublished":"2020-06-16T11:51:30+00:00","dateModified":"2022-10-13T05:23:55+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/latest-covid-happenings-and-pharma-sector#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/16171252\/Latest-Phrma-Happenings.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/16171252\/Latest-Phrma-Happenings.jpg","width":772,"height":482,"caption":"Latest COVID News | Pharma Happenings"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/06\/16171252\/Latest-Phrma-Happenings-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Catalent Biologics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Coronavirus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Emergency Use Authorization<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Olumiant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rheumatoid arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sinovac Biotech<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Catalent Biologics<\/span>","<span class=\"advgb-post-tax-term\">Coronavirus<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Emergency Use Authorization<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Olumiant<\/span>","<span class=\"advgb-post-tax-term\">rheumatoid arthritis<\/span>","<span class=\"advgb-post-tax-term\">Sinovac Biotech<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jun 16, 2020","modified":"Updated on Oct 13, 2022"},"absolute_dates_time":{"created":"Posted on Jun 16, 2020 5:21 pm","modified":"Updated on Oct 13, 2022 10:53 am"},"featured_img_caption":"Latest COVID News | Pharma Happenings","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9605"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9605\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9645"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9605"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9605"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}